From Reuters
Tecentriq Plus Chemo
March 20, 2018: A late-stage study shows Roche’s immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in first-line treatment of people with a type of advanced lung cancer.
“Squamous non-small cell lung cancer is difficult to treat and there have been limited new treatment options over the last few decades,” said Sandra Horning, Roche’s chief medical officer, adding the company was still awaiting overall survival data in its Impower131 study.